Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting

23 March 2015

Novartis (NOVN: VX), Boehringer Ingelheim and Celgene (Nasdaq: CELG) have presented positive data on their dermatology products at the American Academy of Dermatology meeting in San Francisco this weekend.

Novartis' Cosentyx superior to Stelara

New data from Novartis showed that its Cosentyx (secukinumab) is significantly superior to Stelara (ustekinumab), a widely-used biologic, in achieving clear or almost-clear skin for psoriasis patients. Cosentyx met the primary endpoint in a Phase IIIb study of showing superiority to Stelara as assessed by the Psoriasis Area Severity Index (PASI) 90 response, which is clear to almost-clear skin, at week 16.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK